Cohera Medical, Inc.® Enters Agreement with B. Braun Surgical, S.A. for Distribution of TissuGlu® Surgical Adhesive in Select European Countries
PITTSBURGH, Jan. 21, 2015 /PRNewswire/ -- Cohera Medical, Inc.®, a leading innovator and developer of absorbable surgical adhesives and sealants, announced today that it has entered into an exclusive sales and marketing distribution agreement with B. Braun for its TissuGlu® Surgical Adhesive in Germany, Spain and Portugal.
The Agreement outlines a relationship between the two companies wherein B. Braun Surgical, S.A. will exclusively market and sell TissuGlu in the territories of Germany, Spain and Portugal through its existing Closure Technologies commercial teams. TissuGlu has been CE approved and for sale in Germany through a Cohera direct sales force since 2012 and has been used in over 2,000 surgical procedures since that time. TissuGlu is indicated in Europe for the approximation of tissue layers where subcutaneous dead space exists between tissue planes in large flap surgical procedures such as abdominoplasty.
"Cohera is excited to enter the relationship with B. Braun for the marketing of TissuGlu in these European countries," said Patrick Daly, Cohera Medical President and CEO. "We are looking forward to working with such a great organization and to making our breakthrough TissuGlu product available to more surgeons and patients in Europe."
TissuGlu is designed to meet surgeons' need for a strong, biocompatible, and easy-to-use surgical adhesive. TissuGlu is targeted for use in large flap procedures in which drains are used to control fluid output and seroma formation. TissuGlu is currently being utilized in Europe to eliminate drains or reduce complications in patients undergoing large flap surgical procedures such as abdominoplasty (tummy tuck), mastectomy, lymph node dissection, decubitus and latissimus dorsi flap procedures. Over 2,000 procedures have been conducted with TissuGlu bringing great benefit to patients, surgeons, and caregivers.
About Cohera Medical
Cohera Medical, Inc. is a rapidly growing medical device company that is actively developing a line of surgical adhesives and sealants. Cohera Medical's products are based on a unique chemical design that is resorbable, non-toxic, easy-to-use, and forms a strong bond between tissue layers. The Company's lead product, TissuGlu® Surgical Adhesive, is indicated in the EU for the approximation of tissue layers where subcutaneous dead space exists between the tissue planes in large flap surgical procedures such as abdominoplasty. TissuGlu is currently approved for sale in the EU and is being utilized to eliminate drains or reduce complications in patients undergoing large flap surgical procedures such as abdominoplasty (tummy tuck), mastectomy, lymph node dissection, decubitus and latissimus dorsi flap procedures. The Company's second product, Sylys Surgical Sealant, the first synthetic sealant designed specifically to help reduce anastomotic leaks, is currently under the CE Mark approval process. TissuGlu and Sylys are the first in a pipeline of technology that includes surgical mesh adhesives, hemostatic foam, bone adhesives, and drug delivery. Outside of the EU, TissuGlu and the other Cohera Medical products are currently indicated for investigational use only and have not yet been approved for sale by the Food and Drug Administration (FDA) in the U.S. or in any other market.
For more information, visit www.coheramed.com.
About B. Braun Surgical, S.A.
B. Braun is a world leading healthcare supplier and a privately-held family enterprise that celebrated in 2014 175 years of successful business and continuous growth.
B. Braun provides the global healthcare market with products for anesthesia, intensive medicine, cardiology, extra corporeal blood treatment and surgery, as well as services for hospitals, general practitioners and the home care sector.
B. Braun is a company headquartered in Europe but active throughout the world with more than 60 subsidiaries. It consists of four divisions that have expanded over the course of time: Hospital Care, Aesculap, Out Patient Market and B. Braun Avitum which cover different medical fields: hospital, surgery, private practice and extracorporeal blood treatment.
B. Braun Surgical is a subsidiary of the B. Braun Group that belongs to the Aesculap division dealing mainly with surgical instruments, suture materials and services for all core surgical procedures. Specific products and product groups are orthopedics/traumatology, spinal surgery, motor systems, neurosurgery and vascular therapy.
B. Braun Surgical also manages the Center of Excellence of the strategic business unit Closure Technologies based near Barcelona (Spain). It is the reference center of the B. Braun Group and as such is globally responsible for Research and Development, Manufacturing, Quality Assurance, Regulatory Affairs, Strategical Marketing and Supply Chain Management.
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.
SOURCE Cohera Medical, Inc.
Share this article